Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 10, 2017 - Issue 12
Submit an article Journal homepage
577
Views
12
CrossRef citations to date
0
Altmetric
Drug Profile

Atezolizumab in invasive and metastatic urothelial carcinoma

Michael CristLaura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USAView further author information
&
Arjun BalarMedicine, Genitourinary Medical Oncology Program, Laura & Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USACorrespondence[email protected]
View further author information
Pages 1295-1301 | Received 15 Aug 2017, Accepted 04 Oct 2017, Published online: 30 Oct 2017

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mengzhen Jiang, Man Liu, Guodi Liu, Jiawen Ma, Lixin Zhang & Shenlin Wang. (2023) Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1. mAbs 15:1.
Read now

Articles from other publishers (11)

Kaewta Rattanapisit, Christine Joy I. Bulaon, Richard Strasser, Hongyan Sun & Waranyoo Phoolcharoen. (2023) In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody. Scientific Reports 13:1.
Crossref
Johannes Lutz, Michael Meister, Mohamed Habbeddine, Katja Fiedler, Aleksandra Kowalczyk & Regina Heidenreich. (2022) Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity. Cancer Immunology, Immunotherapy 72:5, pages 1075-1087.
Crossref
Tao Yang, Yilin Xiong, Yufei Zeng, Yan Wang, Jing Zeng, Jie Liu, Shangfu Xu & Li-Sheng Li. (2022) Current status of immunotherapy for non-small cell lung cancer. Frontiers in Pharmacology 13.
Crossref
Vishakha Singh, Amit Khurana, Prince Allawadhi, Anil Kumar Banothu, Kala Kumar Bharani & Ralf Weiskirchen. (2021) Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Frontiers in Pharmacology 12.
Crossref
Inken Salewski, Steffen Kuntoff, Andreas Kuemmel, Rico Feldtmann, Stephan B. Felix, Larissa Henze, Christian Junghanss & Claudia Maletzki. (2021) Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors. Cancer Immunology, Immunotherapy 70:12, pages 3405-3419.
Crossref
Muhammad Kalim, Muhammad Saleem Iqbal Khan & Jinbiao Zhan. (2020) Programmed cell death ligand‐1: A dynamic immune checkpoint in cancer therapy. Chemical Biology & Drug Design 95:6, pages 552-566.
Crossref
Hong-Chen Qu, Yan Huang, Zhong-Yi Mu, Hang Lv, Qing-Peng Xie, Kai Wang & Bin Hu. (2020) Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis. Frontiers in Pharmacology 10.
Crossref
Byunghee Yoo, Veronica Clavijo Jordan, Patrick Sheedy, Ann-Marie Billig, Alana Ross, Pamela Pantazopoulos & Zdravka Medarova. (2019) RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy. Scientific Reports 9:1.
Crossref
Ming Yi, Dechao Jiao, Hanxiao Xu, Qian Liu, Weiheng Zhao, Xinwei Han & Kongming Wu. (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer 17:1.
Crossref
Deepika Dhawan, Noah M. Hahn, José A. Ramos-Vara & Deborah W. Knapp. (2018) Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. PLOS Genetics 14:8, pages e1007571.
Crossref
Anjelica Hodgson, Elzbieta Slodkowska, Achim Jungbluth, Stanley K. Liu, Danny Vesprini, Danny Enepekides, Kevin Higgins, Nora Katabi, Bin Xu & Michelle R. Downes. (2018) PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. American Journal of Surgical Pathology 42:8, pages 1059-1066.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.